Get startedLog in
    Picture of Ascendis Pharma A/S logo

    ASND — Ascendis Pharma A/S News Story

    0.000.00%
    us flag iconLast trade - 00:00
    HealthcareBalancedLarge CapHigh Flyer
    All News

    Ascendis Pharma A/S reports results for the quarter ended June 30 - Earnings Summary

    Picture of Ascendis Pharma A/S logoAscendis Pharma A/S
    08/08/2025 04:24
    Ascendis Pharma A/S ASND.OQ reported a quarterly adjusted loss of 64 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of €-1.91.  The mean expectation of fifteen analysts for the quarter was for a loss of €1.25 per share. Wall Street expected results to range from €-1.77 to -79 cents per share.

Revenue rose 339% to €158.05 million from a year ago; analysts expected €141.55 million.

Ascendis Pharma A/S's reported EPS for the quarter was a loss of 64 cents​.

The company reported a quarterly loss of €38.86 million.

Ascendis Pharma A/S shares had risen by 5.8% this quarter and gained 32.6% so far this year.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 6.1% in the last three months.​

In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 17 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Ascendis Pharma A/S is $224.50, about 15.2% above its last closing price of $190.35

This summary was machine generated from LSEG data August 8 at 03:24 a.m. UTC. ​All figures in euros unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)


    QUARTER ENDINGESTIMATEACTUALBEAT, MET, MISSED
    Jun. 30 2025-1.25-0.64Beat
    Mar. 31 2025-1.49-1.58Missed
    Dec. 31 2024-0.96-0.64Beat
    Sep. 30 2024-1.74-1.72Beat

    Recent news on Ascendis Pharma A/S

    See all news